Sectors

ANGO
AngioDynamics, Inc.
16.13
2 x 11.38
1 x 16.04
bid
ask
+
0.28
1.77%
2 @ 04:00 PM
16.13 +0.00 (0.00%)
Ytd25.62%
1y57.21%
15.63
day range
16.22
9.39
52 week range
16.29
Open15.80Prev Close15.85Low15.63High16.22Mkt Cap666.69M
Vol346.06KAvg Vol442.30KEPS-0.88P/EN/AForward P/E-36.21
Beta0.67Short Ratio2.88Inst. Own81.31%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning10-0150-d Avg14.32200-d Avg12.151yr Est13.00

ANGO News

AngioDynamics, Inc. $ANGO Shares Purchased by Bank of America Corp DE
defenseworld.net
AngioDynamics, Inc. $ANGO Shares Purchased by Bank of America Corp DE

Bank of America Corp DE grew its holdings in shares of AngioDynamics, Inc. (NASDAQ: ANGO) by 262.7%

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
zacks.com
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
marketbeat.com
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
zacks.com
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising c

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus
zacks.com
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
zacks.com
ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?

AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative

AngioDynamics to Participate in Upcoming Investor Conferences
gurufocus.com
AngioDynamics to Participate in Upcoming Investor Conferences

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused

AngioDynamics to Participate in Upcoming Investor Conferences
businesswire.com
AngioDynamics to Participate in Upcoming Investor Conferences

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medi

AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)
seekingalpha.com
AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)

AngioDynamics develops tools for minimally invasive procedures across blood flow, blocked arteries,

benzinga.com
HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19

HC Wainwright & Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:ANGO) with a Buy and rais

AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands
zacks.com
AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands

ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27

benzinga.com
Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20

Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and raises

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript
seekingalpha.com
AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics Q4 Earnings Call Highlights
marketbeat.com
AngioDynamics Q4 Earnings Call Highlights

AngioDynamics NASDAQ: ANGO reported higher fiscal fourth-quarter and full-year revenue, driven by co

Full Transcript: AngioDynamics Q4 2026 Earnings Call
benzinga.com
Full Transcript: AngioDynamics Q4 2026 Earnings Call

AngioDynamics (NASDAQ:ANGO) released fourth-quarter financial results and hosted an earnings call on

AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates
zacks.com
AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates

AngioDynamics (ANGO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Es

Earnings Scheduled For July 14, 2026
benzinga.com
Earnings Scheduled For July 14, 2026

Companies Reporting Before The Bell • Grupo Aeroportuario del (NYSE:PAC) is likely to report quarter

benzinga.com
AngioDynamics Sees FY2027 Adj EPS $(0.29)-$(0.24) vs $(0.16) Est; Sees Sales $336.000M-$341.000M vs

AngioDynamics (NASDAQ:ANGO) is looking for FY2027 Adj EPS of $(0.29)-$(0.24) vs $(0.16) analyst esti

benzinga.com
AngioDynamics Q4 Adj. EPS $(0.07) Beats $(0.09) Estimate, Sales $86.607M Beat $80.400M Estimate

AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.07) per share which beat the analyst co

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
businesswire.com
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Contin

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medi

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
businesswire.com
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focu

Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
zacks.com
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now

ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock des

ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study
zacks.com
ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study

AngioDynamics' FDA IDE approval for RELIEF advances NanoKnife IRE study as a potential minimally inv

benzinga.com
AngioDynamics Says FDA Approves IDE Application To Initiate RELIEF Study Evaluating NanoKnife IRE Pl

AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood f

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
businesswire.com
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platfo

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focu

AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
seekingalpha.com
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 P

AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 P

Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session
benzinga.com
Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stock

U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
businesswire.com
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Cove

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focu

benzinga.com
AngioDynamics Announces 2-Yr Results From PRESERVE Pivotal Trial Demonstrating Durable Oncologic Con

Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 monthsResults Presented

benzinga.com
Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16

Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers

Earnings Scheduled For April 2, 2026
benzinga.com
Earnings Scheduled For April 2, 2026

benzinga.com
AngioDynamics Raises FY2026 Adj EPS Guidance from $(0.33)-$(0.23) to $(0.30)-$(0.23) vs $(0.29) Est;

AngioDynamics (NASDAQ:ANGO) raises FY2026 Adj EPS guidance from $(0.33)-$(0.23) to $(0.30)-$(0.23) v

benzinga.com
AngioDynamics Q3 Adj. EPS $(0.07) Beats $(0.11) Estimate, Sales $78.423M Beat $76.767M Estimate

AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.07) per share which beat the analyst co

Nasdaq Gains Over 1% On War De-Escalation Hopes: Investor Fear Eases, But Fear & Greed Index Remains In 'Extreme Fear' Zone
benzinga.com
Nasdaq Gains Over 1% On War De-Escalation Hopes: Investor Fear Eases, But Fear & Greed Index Remains

Stocks end higher, Fear & Greed Index eases, Trump suggests quick military withdrawal from Iran,

Acuity, Lindsay And 3 Stocks To Watch Heading Into Thursday
benzinga.com
Acuity, Lindsay And 3 Stocks To Watch Heading Into Thursday

U.S. stock futures trading lower, Acuity and Visionary Holdings report strong earnings, Lindsay Cor

benzinga.com
AngioDynamics Expands European Indications For NanoKnife System To Include Soft Tissue Ablation For

Growing Clinical Evidence and Physician Adoption Broaden NanoKnife IRE Technology as Treatment Optio

Dow Jumps Over 400 Points; US Services Activity Falls In December
benzinga.com
Dow Jumps Over 400 Points; US Services Activity Falls In December

US Stocks Mixed; Nasdaq Gains Over 50 Points
benzinga.com
US Stocks Mixed; Nasdaq Gains Over 50 Points

Earnings Scheduled For January 6, 2026
benzinga.com
Earnings Scheduled For January 6, 2026

benzinga.com
AngioDynamics Affirms FY2026 Adj EPS Guidance of $(0.33)-$(0.23) vs $(0.33) Est; Raises FY2026 Sales

Fiscal Year 2026 Financial GuidanceFor fiscal year 2026 the company now expects:Guidance Metric Guid

AngioDynamics, Microchip Technology And 3 Stocks To Watch Heading Into Tuesday
benzinga.com
AngioDynamics, Microchip Technology And 3 Stocks To Watch Heading Into Tuesday

U.S. stock futures up, focus on AngioDynamics, Microchip Tech, AAR earnings. Galapagos to wind down

Dow Hits Record High After US Strike On Venezuela: Investor Sentiment Improves, Fear & Greed Index Remains In 'Neutral Zone
benzinga.com
Dow Hits Record High After US Strike On Venezuela: Investor Sentiment Improves, Fear & Greed Index R

U.S. stocks rise on Venezuela raids, Dow hits record high. CNN Money Fear and Greed Index improves b

What to Expect from AngioDynamics's Earnings
benzinga.com
What to Expect from AngioDynamics's Earnings

AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
benzinga.com
AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings

AngioDynamics Eyes Growth Despite Tariffs
benzinga.com
AngioDynamics Eyes Growth Despite Tariffs

AngioDynamics (ANGO) exceeds expectations, raises guidance for fiscal 2026 with positive cash flow e

benzinga.com
Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $18

Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:ANGO) with a Buy and r

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher
benzinga.com
Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on

What's Fueling The Momentum In AngioDynamics Stock?
benzinga.com
What's Fueling The Momentum In AngioDynamics Stock?

Shares of AngioDynamics, Inc. (NASDAQ: ANGO) are up Thursday after the biotechnology company raised

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results
benzinga.com
Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results